Shares of Exact Sciences Corp. (NASDAQ:EXAS) were down 2% during mid-day trading on Tuesday . The company traded as low as $20.31 and last traded at $20.38, with a volume of 1,163,160 shares trading hands. The stock had previously closed at $20.80.

A number of analysts recently issued reports on EXAS shares. Canaccord Genuity reissued a “buy” rating and set a $9.00 price objective on shares of Exact Sciences Corp. in a research report on Monday, May 2nd. Mizuho cut Exact Sciences Corp. from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $12.00 to $6.50 in a research report on Wednesday, May 4th. Jefferies Group reaffirmed a “buy” rating on shares of Exact Sciences Corp. in a research report on Wednesday, May 4th. Zacks Investment Research cut Exact Sciences Corp. from a “buy” rating to a “hold” rating in a research report on Friday, May 6th. Finally, BTIG Research reaffirmed a “buy” rating on shares of Exact Sciences Corp. in a research report on Tuesday, May 10th. Seven research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Exact Sciences Corp. currently has an average rating of “Buy” and a consensus price target of $16.32.

The stock’s 50-day moving average is $16.70 and its 200 day moving average is $9.58. The stock’s market cap is $1.87 billion.

Exact Sciences Corp. (NASDAQ:EXAS) last released its earnings results on Tuesday, July 26th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.55) by $0.09. The firm had revenue of $21.20 million for the quarter, compared to the consensus estimate of $18.54 million. Exact Sciences Corp.’s revenue for the quarter was up 161.7% on a year-over-year basis. During the same quarter last year, the company posted ($0.44) EPS. Equities research analysts anticipate that Exact Sciences Corp. will post ($1.79) EPS for the current fiscal year.

In other Exact Sciences Corp. news, COO Maneesh Arora sold 7,359 shares of the stock in a transaction dated Tuesday, July 26th. The stock was sold at an average price of $14.82, for a total transaction of $109,060.38. Following the completion of the transaction, the chief operating officer now owns 538,736 shares in the company, valued at approximately $7,984,067.52. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Katherine S. Zanotti bought 3,380 shares of the stock in a transaction on Wednesday, August 3rd. The shares were purchased at an average price of $17.93 per share, with a total value of $60,603.40. Following the acquisition, the director now owns 105,927 shares in the company, valued at approximately $1,899,271.11. The disclosure for this purchase can be found here.

Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of some forms of cancer. The Company’s product pipeline includes Lung Cancer Nodules, Pancreatic Cancer Screening, Esophageal Cancer Screening, Lung Cancer Pipeline, Pancreatic Cancer Pipeline and Esophageal Cancer Pipeline.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.